Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2475 entries
Sorted by: Best Match Show Resources per page
Intracranial Hemorrhage in the TST Trial.

Stroke

Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lavallée PC, Lee BC, Mahagne MH, Meseguer E, Nighoghossian N, Steg PG, Vicaut É, Bruckert E.
PMID: 34963300
Stroke. 2021 Dec 29;STROKEAHA121035846. doi: 10.1161/STROKEAHA.121.035846. Epub 2021 Dec 29.

BACKGROUND AND PURPOSE: Although statins are effective in secondary prevention of ischemic stroke, they are also associated with an increase risk of intracranial hemorrhage (ICH) in certain conditions. In the TST trial (Treat Stroke to Target), we prespecified an...

Cite
Amarenco P, Kim JS, Labreuche J, et al. Intracranial Hemorrhage in the TST Trial. Stroke. 2021;STROKEAHA121035846doi: 10.1161/STROKEAHA.121.035846.
Amarenco, P., Kim, J. S., Labreuche, J., Charles, H., Giroud, M., Lavallée, P. C., Lee, B. C., Mahagne, M. H., Meseguer, E., Nighoghossian, N., Steg, P. G., Vicaut, �. �., Bruckert, E. (2021). Intracranial Hemorrhage in the TST Trial. Stroke, STROKEAHA121035846. https://doi.org/10.1161/STROKEAHA.121.035846
Amarenco, Pierre, et al. "Intracranial Hemorrhage in the TST Trial." Stroke vol. (2021): STROKEAHA121035846. doi: https://doi.org/10.1161/STROKEAHA.121.035846
Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lavallée PC, Lee BC, Mahagne MH, Meseguer E, Nighoghossian N, Steg PG, Vicaut É, Bruckert E. Intracranial Hemorrhage in the TST Trial. Stroke. 2021 Dec 29;STROKEAHA121035846. doi: 10.1161/STROKEAHA.121.035846. Epub 2021 Dec 29. PMID: 34963300.
Copy Download .nbib Format: NLM
Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia.

Stroke

Hovland A, Mundal LJ, Igland J, Veierød MB, Holven KB, Bogsrud MP, Tell GS, Leren TP, Retterstøl K.
PMID: 30580708
Stroke. 2018 Nov 21;STROKEAHA118023456. doi: 10.1161/STROKEAHA.118.023456. Epub 2018 Nov 21.

Background and Purpose- Familial hypercholesterolemia (FH) is a common autosomal dominant disease leading to increased level of serum LDL (low-density lipoprotein) cholesterol and risk of coronary heart disease. Whether FH increases the risk of cerebrovascular disease, including ischemic stroke,...

Cite
Hovland A, Mundal LJ, Igland J, et al. Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia. Stroke. 2018;STROKEAHA118023456doi: 10.1161/STROKEAHA.118.023456.
Hovland, A., Mundal, L. J., Igland, J., Veierød, M. B., Holven, K. B., Bogsrud, M. P., Tell, G. S., Leren, T. P., & Retterstøl, K. (2018). Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia. Stroke, STROKEAHA118023456. https://doi.org/10.1161/STROKEAHA.118.023456
Hovland, Anders, et al. "Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia." Stroke vol. (2018): STROKEAHA118023456. doi: https://doi.org/10.1161/STROKEAHA.118.023456
Hovland A, Mundal LJ, Igland J, Veierød MB, Holven KB, Bogsrud MP, Tell GS, Leren TP, Retterstøl K. Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia. Stroke. 2018 Nov 21;STROKEAHA118023456. doi: 10.1161/STROKEAHA.118.023456. Epub 2018 Nov 21. PMID: 30580708.
Copy Download .nbib Format: NLM
Coronary Artery Disease and Its Risk Factors: Leveraging Shared Genetics to Discover Novel Biology.

Circulation research

Quertermous T, Ingelsson E.
PMID: 26837740
Circ Res. 2016 Jan 08;118(1):14-6. doi: 10.1161/CIRCRESAHA.115.307937.

No abstract available.

Cite
Quertermous T, Ingelsson E. Coronary Artery Disease and Its Risk Factors: Leveraging Shared Genetics to Discover Novel Biology. Circ Res. 2016;118(1):14-6doi: 10.1161/CIRCRESAHA.115.307937.
Quertermous, T., & Ingelsson, E. (2016). Coronary Artery Disease and Its Risk Factors: Leveraging Shared Genetics to Discover Novel Biology. Circulation research, 118(1), 14-6. https://doi.org/10.1161/CIRCRESAHA.115.307937
Quertermous, Thomas, and Ingelsson, Erik. "Coronary Artery Disease and Its Risk Factors: Leveraging Shared Genetics to Discover Novel Biology." Circulation research vol. 118,1 (2016): 14-6. doi: https://doi.org/10.1161/CIRCRESAHA.115.307937
Quertermous T, Ingelsson E. Coronary Artery Disease and Its Risk Factors: Leveraging Shared Genetics to Discover Novel Biology. Circ Res. 2016 Jan 08;118(1):14-6. doi: 10.1161/CIRCRESAHA.115.307937. PMID: 26837740; PMCID: PMC4743893.
Copy Download .nbib Format: NLM
Lipid Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in Dubai: A Five-year Pattern.

Oman medical journal

Abdelgadir E, Alsaeed M, Hafidh K, Bashier A, Rashid F, Altayb F, Sayyah F, Farooqi MH, Alawadi F.
PMID: 31360316
Oman Med J. 2019 Jul;34(4):290-296. doi: 10.5001/omj.2019.58.

OBJECTIVES: A key aspect for the prevention of vascular complications in diabetes is control of hyperlipidemia, and that has always been a global challenge. The prevalence of diabetes mellitus in the UAE is estimated to be 18.98%. However, despite...

Cite
Abdelgadir E, Alsaeed M, Hafidh K, et al. Lipid Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in Dubai: A Five-year Pattern. Oman Med J. 2019;34(4):290-296doi: 10.5001/omj.2019.58.
Abdelgadir, E., Alsaeed, M., Hafidh, K., Bashier, A., Rashid, F., Altayb, F., Sayyah, F., Farooqi, M. H., & Alawadi, F. (2019). Lipid Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in Dubai: A Five-year Pattern. Oman medical journal, 34(4), 290-296. https://doi.org/10.5001/omj.2019.58
Abdelgadir, Elamin, et al. "Lipid Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in Dubai: A Five-year Pattern." Oman medical journal vol. 34,4 (2019): 290-296. doi: https://doi.org/10.5001/omj.2019.58
Abdelgadir E, Alsaeed M, Hafidh K, Bashier A, Rashid F, Altayb F, Sayyah F, Farooqi MH, Alawadi F. Lipid Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in Dubai: A Five-year Pattern. Oman Med J. 2019 Jul;34(4):290-296. doi: 10.5001/omj.2019.58. PMID: 31360316; PMCID: PMC6642714.
Copy Download .nbib Format: NLM
Contribution of hypertriglyceridemia to ischemic cardiovascular disease in Korean Women: A nationwide population-based study.

Journal of clinical lipidology

Choe HJ, Park S, Han KD, Moon MK, Koo BK.
PMID: 34896034
J Clin Lipidol. 2021 Nov 27; doi: 10.1016/j.jacl.2021.11.008. Epub 2021 Nov 27.

BACKGROUND: The independent effect of serum triglyceride levels on the development of ischemic cardiovascular disease (CVD) remains inconclusive, which might be due to heterogeneity among study populations.OBJECTIVE: To evaluate the effect of triglyceride levels on ischemic CVD and mortality...

Cite
Choe HJ, Park S, Han KD, et al. Contribution of hypertriglyceridemia to ischemic cardiovascular disease in Korean Women: A nationwide population-based study. J Clin Lipidol. 2021;doi: 10.1016/j.jacl.2021.11.008.
Choe, H. J., Park, S., Han, K. D., Moon, M. K., & Koo, B. K. (2021). Contribution of hypertriglyceridemia to ischemic cardiovascular disease in Korean Women: A nationwide population-based study. Journal of clinical lipidology, . https://doi.org/10.1016/j.jacl.2021.11.008
Choe, Hun Jee, et al. "Contribution of hypertriglyceridemia to ischemic cardiovascular disease in Korean Women: A nationwide population-based study." Journal of clinical lipidology vol. (2021). doi: https://doi.org/10.1016/j.jacl.2021.11.008
Choe HJ, Park S, Han KD, Moon MK, Koo BK. Contribution of hypertriglyceridemia to ischemic cardiovascular disease in Korean Women: A nationwide population-based study. J Clin Lipidol. 2021 Nov 27; doi: 10.1016/j.jacl.2021.11.008. Epub 2021 Nov 27. PMID: 34896034.
Copy Download .nbib Format: NLM
Impact of training primary care physicians in behavioral counseling to reduce cardiovascular disease risk factors in Ecuador.

Revista panamericana de salud publica = Pan American journal of public health

Baldeón ME, Fornasini M, Flores N, Merriam PA, Rosal M, Zevallos JC, Ocken I.
PMID: 31093167
Rev Panam Salud Publica. 2018 Sep 24;42:e139. doi: 10.26633/RPSP.2018.139. eCollection 2018.

OBJECTIVE: To assess the feasibility of implementing a physician-based, patient-centered counseling intervention model in Ecuador to improve the ability of primary care physicians (PCPs) to reduce cardiovascular disease (CVD) risk factors among patients.METHODS: This was a randomized clinical trial...

Cite
Baldeón ME, Fornasini M, Flores N, et al. Impact of training primary care physicians in behavioral counseling to reduce cardiovascular disease risk factors in Ecuador. Rev Panam Salud Publica. 2018;42:e139doi: 10.26633/RPSP.2018.139.
Baldeón, M. E., Fornasini, M., Flores, N., Merriam, P. A., Rosal, M., Zevallos, J. C., & Ocken, I. (2018). Impact of training primary care physicians in behavioral counseling to reduce cardiovascular disease risk factors in Ecuador. Revista panamericana de salud publica = Pan American journal of public health, 42e139. https://doi.org/10.26633/RPSP.2018.139
Baldeón, Manuel E, et al. "Impact of training primary care physicians in behavioral counseling to reduce cardiovascular disease risk factors in Ecuador." Revista panamericana de salud publica = Pan American journal of public health vol. 42 (2018): e139. doi: https://doi.org/10.26633/RPSP.2018.139
Baldeón ME, Fornasini M, Flores N, Merriam PA, Rosal M, Zevallos JC, Ocken I. Impact of training primary care physicians in behavioral counseling to reduce cardiovascular disease risk factors in Ecuador. Rev Panam Salud Publica. 2018 Sep 24;42:e139. doi: 10.26633/RPSP.2018.139. eCollection 2018. PMID: 31093167; PMCID: PMC6386001.
Copy Download .nbib Format: NLM
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.

Annals of translational medicine

Kosmas CE, Sourlas A, Bouza KV, DeJesus E, Silverio D, Montan PD, Guzman E.
PMID: 29955590
Ann Transl Med. 2018 Apr;6(7):130. doi: 10.21037/atm.2018.02.20.

No abstract available.

Cite
Kosmas CE, Sourlas A, Bouza KV, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. Ann Transl Med. 2018;6(7):130doi: 10.21037/atm.2018.02.20.
Kosmas, C. E., Sourlas, A., Bouza, K. V., DeJesus, E., Silverio, D., Montan, P. D., & Guzman, E. (2018). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. Annals of translational medicine, 6(7), 130. https://doi.org/10.21037/atm.2018.02.20
Kosmas, Constantine E, et al. "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus." Annals of translational medicine vol. 6,7 (2018): 130. doi: https://doi.org/10.21037/atm.2018.02.20
Kosmas CE, Sourlas A, Bouza KV, DeJesus E, Silverio D, Montan PD, Guzman E. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. Ann Transl Med. 2018 Apr;6(7):130. doi: 10.21037/atm.2018.02.20. PMID: 29955590; PMCID: PMC6015935.
Copy Download .nbib Format: NLM
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583.

The American journal of cardiology

Baruch A, Mosesova S, Davis JD, Budha N, Vilimovskij A, Kahn R, Peng K, Cowan KJ, Harris LP, Gelzleichter T, Lehrer J, Davis JC, Tingley WG.
PMID: 29448977
Am J Cardiol. 2018 Aug 01;122(3):527. doi: 10.1016/j.amjcard.2018.01.010. Epub 2018 Feb 12.

No abstract available.

Cite
Baruch A, Mosesova S, Davis JD, et al. Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583. Am J Cardiol. 2018;122(3):527doi: 10.1016/j.amjcard.2018.01.010.
Baruch, A., Mosesova, S., Davis, J. D., Budha, N., Vilimovskij, A., Kahn, R., Peng, K., Cowan, K. J., Harris, L. P., Gelzleichter, T., Lehrer, J., Davis, J. C., & Tingley, W. G. (2018). Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583. The American journal of cardiology, 122(3), 527. https://doi.org/10.1016/j.amjcard.2018.01.010
Baruch, Amos, et al. "Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583." The American journal of cardiology vol. 122,3 (2018): 527. doi: https://doi.org/10.1016/j.amjcard.2018.01.010
Baruch A, Mosesova S, Davis JD, Budha N, Vilimovskij A, Kahn R, Peng K, Cowan KJ, Harris LP, Gelzleichter T, Lehrer J, Davis JC, Tingley WG. Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583. Am J Cardiol. 2018 Aug 01;122(3):527. doi: 10.1016/j.amjcard.2018.01.010. Epub 2018 Feb 12. PMID: 29448977.
Copy Download .nbib Format: NLM
Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh.

Indian journal of clinical biochemistry : IJCB

Malati T, Mahesh MR.
PMID: 23105859
Indian J Clin Biochem. 2009 Oct;24(4):343-55. doi: 10.1007/s12291-009-0063-5. Epub 2009 Dec 30.

The incidence of cardiovascular and cerebrovascular disease is steadily increasing in South East Asian countries including Indian sub continent. Many lipids, apolipoproteins and Lp (a) except HDL-C and apo A-I, A-II are implicated as risk factors for coronary artery...

Cite
Malati T, Mahesh MR. Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh. Indian J Clin Biochem. 2009;24(4):343-55doi: 10.1007/s12291-009-0063-5.
Malati, T., & Mahesh, M. R. (2009). Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh. Indian journal of clinical biochemistry : IJCB, 24(4), 343-55. https://doi.org/10.1007/s12291-009-0063-5
Malati, T, and Mahesh, M R U. "Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh." Indian journal of clinical biochemistry : IJCB vol. 24,4 (2009): 343-55. doi: https://doi.org/10.1007/s12291-009-0063-5
Malati T, Mahesh MR. Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh. Indian J Clin Biochem. 2009 Oct;24(4):343-55. doi: 10.1007/s12291-009-0063-5. Epub 2009 Dec 30. PMID: 23105859; PMCID: PMC3453058.
Copy Download .nbib Format: NLM
Low-density lipoprotein apheresis: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]
PMID: 23074505
Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 01.

OBJECTIVE: To assess the effectiveness and safety of low-density lipoprotein (LDL) apheresis performed with the heparin-induced extracorporeal LDL precipitation (HELP) system for the treatment of patients with refractory homozygous (HMZ) and heterozygous (HTZ) familial hypercholesterolemia (FH). BACKGROUND ON FAMILIAL...

Cite
Low-density lipoprotein apheresis: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;7(5):1-101
(2007). Low-density lipoprotein apheresis: an evidence-based analysis. Ontario health technology assessment series, 7(5), 1-101.
"Low-density lipoprotein apheresis: an evidence-based analysis." Ontario health technology assessment series vol. 7,5 (2007): 1-101.
Low-density lipoprotein apheresis: an evidence-based analysis. Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 01. PMID: 23074505; PMCID: PMC3377562.
Copy Download .nbib Format: NLM
Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative.

Current medical research and opinion

Irawati S, Emmens JE, de Vos S, Bos JHJ, de Boer RA, Hak E.
PMID: 34555980
Curr Med Res Opin. 2021 Oct 19;1-6. doi: 10.1080/03007995.2021.1984222. Epub 2021 Oct 19.

OBJECTIVE: To investigate whether statin adherence (defined as proportion days covered, PDC) is associated with LDL-c response in statin initiators on standard and low starting doses of statins, and to detect a possible interaction with sex.METHODS: An inception cohort...

Cite
Irawati S, Emmens JE, de Vos S, et al. Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Curr Med Res Opin. 2021;1-6doi: 10.1080/03007995.2021.1984222.
Irawati, S., Emmens, J. E., de Vos, S., Bos, J. H. J., de Boer, R. A., & Hak, E. (2021). Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Current medical research and opinion, 1-6. https://doi.org/10.1080/03007995.2021.1984222
Irawati, Sylvi, et al. "Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative." Current medical research and opinion vol. (2021): 1-6. doi: https://doi.org/10.1080/03007995.2021.1984222
Irawati S, Emmens JE, de Vos S, Bos JHJ, de Boer RA, Hak E. Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Curr Med Res Opin. 2021 Oct 19;1-6. doi: 10.1080/03007995.2021.1984222. Epub 2021 Oct 19. PMID: 34555980.
Copy Download .nbib Format: NLM
Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative.

Current medical research and opinion

Irawati S, Emmens JE, de Vos S, Bos JHJ, de Boer RA, Hak E.
PMID: 34555980
Curr Med Res Opin. 2022 Jan;38(1):1-6. doi: 10.1080/03007995.2021.1984222. Epub 2021 Oct 19.

OBJECTIVE: To investigate whether statin adherence (defined as proportion days covered, PDC) is associated with LDL-c response in statin initiators on standard and low starting doses of statins, and to detect a possible interaction with sex.METHODS: An inception cohort...

Cite
Irawati S, Emmens JE, de Vos S, et al. Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Curr Med Res Opin. 2021;38(1):1-6doi: 10.1080/03007995.2021.1984222.
Irawati, S., Emmens, J. E., de Vos, S., Bos, J. H. J., de Boer, R. A., & Hak, E. (2022). Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Current medical research and opinion, 38(1), 1-6. https://doi.org/10.1080/03007995.2021.1984222
Irawati, Sylvi, et al. "Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative." Current medical research and opinion vol. 38,1 (2022): 1-6. doi: https://doi.org/10.1080/03007995.2021.1984222
Irawati S, Emmens JE, de Vos S, Bos JHJ, de Boer RA, Hak E. Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Curr Med Res Opin. 2022 Jan;38(1):1-6. doi: 10.1080/03007995.2021.1984222. Epub 2021 Oct 19. PMID: 34555980.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2475 entries